Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Lindblad Expeditions swings to Q3 net profit available to stockholders of $24.24 million; Q3 tour revenues rise 12% to $269.15 million

Lindblad Expeditions swings to Q3 net profit available to stockholders of $24.24 million; Q3 tour revenues rise 12% to $269.15 million

BitgetBitget2026/11/03 12:33
  • Lindblad Expeditions Holdings swung to third-quarter 2026 net income available to stockholders of $24.24 million from a year-earlier loss.
  • Tour revenues rose 12% year over year to $269.15 million, with growth across both operating segments.
  • The group acquired majority ownership interests in luxury Antarctic operator White Desert and specialized aviation travel brand Echo Charlie.
  • Full-year 2026 tour revenues are expected to reach $870 million–$885 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lindblad Expeditions Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY87199) on November 03, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss